TG Therapeutics | TGTX - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 14.39B 1.85B 2026-06
Alaunos Therapeutics USD -1.13M 1.11M 2024-09
Amgen USD 5.87B 1.02B 2026-03
Ardelyx USD 89.66M 24.7M 2026-03
Arrowhead Research USD 75.25M 1.52M 2026-06
Bayer EUR 6.33B 1.84B 2026-06
Biogen USD 2.12B 307M 2026-06
Corcept Therapeutics USD 252.09M 90.07M 2026-06
Curis USD 1.14M 8.86M 2025-12
Gilead Sciences USD 6.8B 1.29B 2026-06
J&J USD 18.55B 1.31B 2026-06
Karyopharm Therapeutics USD 33.72M 1.13M 2026-03
Novartis USD 11.24B 1.18B 2026-06
Novavax USD 125.04M 76.09M 2025-12
PTC Therapeutics USD 232.94M 84.56M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Roche Holding CHF 22.69B 600M 2026-06
TG Therapeutics USD 199.14M 27.73M 2026-06
Verastem USD 15.62M 977K 2026-03
Vertex Pharmaceuticals USD 2.84B 242.4M 2026-06